Abstract
In 2000, Wyeth reported that the 3-quinolinecarbonitrile ring system was a template for EGFR inhibitors. It soon became apparent that the group at C-4 of this core was responsible for kinase selectivity. A 4-(2,4-dichloro-5- methoxyanilino) substituent provided potent inhibitors of Src, a non-receptor tyrosine kinase that plays a key role in cell signaling. One compound from this series, SKI-606, bosutinib, is currently in clinical trials for the treatment of cancer.
Keywords: 3-Quinolinecarbonitrile, kinase, Src, cancer, Abl, CML, SKI-606, bosutinib
Current Topics in Medicinal Chemistry
Title: Exploitation of the 3-Quinolinecarbonitrile Template for Src Tyrosine Kinase Inhibitors
Volume: 8 Issue: 10
Author(s): Diane H. Boschelli
Affiliation:
Keywords: 3-Quinolinecarbonitrile, kinase, Src, cancer, Abl, CML, SKI-606, bosutinib
Abstract: In 2000, Wyeth reported that the 3-quinolinecarbonitrile ring system was a template for EGFR inhibitors. It soon became apparent that the group at C-4 of this core was responsible for kinase selectivity. A 4-(2,4-dichloro-5- methoxyanilino) substituent provided potent inhibitors of Src, a non-receptor tyrosine kinase that plays a key role in cell signaling. One compound from this series, SKI-606, bosutinib, is currently in clinical trials for the treatment of cancer.
Export Options
About this article
Cite this article as:
Boschelli H. Diane, Exploitation of the 3-Quinolinecarbonitrile Template for Src Tyrosine Kinase Inhibitors, Current Topics in Medicinal Chemistry 2008; 8 (10) . https://dx.doi.org/10.2174/156802608784911653
DOI https://dx.doi.org/10.2174/156802608784911653 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy of Fluorescence Technology vs Conventional Oral Examination for the Early Detection of Oral Pre-Malignant Lesions. A Clinical Comparative Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine Induction of Senescent-Like Growth Arrest as a New Target in Anticancer Treatment
Current Cancer Drug Targets Molecular Dynamics in Esophageal Adenocarcinoma: Who’s in Control?
Current Cancer Drug Targets Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery Radiation Exposure of Anaesthetists Visualised by Real-time Dosimetry
Current Medical Imaging The Role of Androgen Under Normal and Pathological Conditions in Sebaceous Glands: The Possibility of Target Therapy
Current Molecular Pharmacology COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry Managing Skin Malignancies- How Family Doctors, Plastic Surgeons, and Dermatologists Can Help
Current Cancer Therapy Reviews Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, their Niche and Targeted Therapy
Current Stem Cell Research & Therapy Engineered Peptides for Applications in Cancer-Targeted Drug Delivery and Tumor Detection
Mini-Reviews in Medicinal Chemistry Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies Approaches for Imaging the Diabetic Pancreas: First Results
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cytotoxicity of Novel Sulfanilamides Towards Sensitive and Multidrugresistant Leukemia Cells
Current Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Current Pharmaceutical Design CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets